Drug Safety Update - February 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for February 2025 (PDF).
This issue advises healthcare professionals that review by two specialists remains in place for patients initiating valproate under 55 years of age but the Commission on Human Medicines (CHM) has advised that it will not be required for men (or males) currently taking valproate. To aid the decision making process for initiation and review, three infographics have been produced, for female patients under 55 years old, for male patients under 55 years old and for male and female patients 55 years and older. Patients are recommended to continue taking valproate until reviewed by their specialist.
Lastly, this issue contains a summary of letters to healthcare professionals in January. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « NICE Guidance - February 2025 | CKS Updates - February 2025 » |
Leave a Comment